Literature DB >> 17483061

Bacterial bloodstream infection in neutropenic adult patients after myeloablative cord blood transplantation: experience of a single institution in Japan.

Akira Tomonari1, Satoshi Takahashi, Jun Ooi, Nobuhiro Tsukada, Takaaki Konuma, Takeshi Kobayashi, Aki Sato, Kashiya Takasugi, Tohru Iseki, Arinobu Tojo, Shigetaka Asano.   

Abstract

Bacterial infection is one of the most important causes of morbidity and mortality after unrelated cord blood transplantation (CBT). In the present study, we studied 101 adult patients with respect to the incidence, outcome, and risk factors for bacterial bloodstream infection (BSI) within 30 days after CBT using a myeloablative conditioning regimen. Bacterial BSI occurred in 12 patients within 30 days after CBT. The cumulative incidence of bacterial BSI was 12%. The median time of onset was day +6 (range, day -1 to day +13) after CBT. In all patients, the neutrophil count was 0/microL at the onset of bacterial BSI. Eight (67%) and 4 (33%) of the isolates were Gram-positive and Gram-negative bacteria, respectively. Only 2 (17%) of the 12 patients who had bacterial BSI died within 100 days after CBT. No risk factors for the occurrence of bacterial BSI within 30 days after CBT were identified. The low mortality rate for bacterial BSI in the neutropenic period appeared to be associated with the low incidence (6%) of transplantation-related death at day +100 in our study patients. Early diagnosis of bacterial BSI and prompt treatment with effective antibiotics are necessary for neutropenic adult patients after myeloablative CBT.

Entities:  

Mesh:

Year:  2007        PMID: 17483061     DOI: 10.1532/IJH97.06179

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  10 in total

1.  2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.

Authors:  Walter T Hughes; Donald Armstrong; Gerald P Bodey; Eric J Bow; Arthur E Brown; Thierry Calandra; Ronald Feld; Philip A Pizzo; Kenneth V I Rolston; Jerry L Shenep; Lowell S Young
Journal:  Clin Infect Dis       Date:  2002-02-13       Impact factor: 9.079

2.  Early infections in adult patients undergoing unrelated donor cord blood transplantation.

Authors:  S Saavedra; G F Sanz; I Jarque; F Moscardó; C Jiménez; I Lorenzo; G Martín; J Martínez; J De La Rubia; R Andreu; S Mollá; I Llopis; M J Fernández; M Salavert; B Acosta; M Gobernado; M A Sanz
Journal:  Bone Marrow Transplant       Date:  2002-12       Impact factor: 5.483

3.  Bloodstream infection after umbilical cord blood transplantation using reduced-intensity stem cell transplantation for adult patients.

Authors:  Hiroto Narimatsu; Tomoko Matsumura; Masahiro Kami; Shigesaburo Miyakoshi; Eiji Kusumi; Shinsuke Takagi; Yuji Miura; Daisuke Kato; Chiho Inokuchi; Tomohiro Myojo; Yukiko Kishi; Naoko Murashige; Koichiro Yuji; Kazuhiro Masuoka; Akiko Yoneyama; Atsushi Wake; Shinichi Morinaga; Yoshinobu Kanda; Shuichi Taniguchi
Journal:  Biol Blood Marrow Transplant       Date:  2005-06       Impact factor: 5.742

4.  Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients.

Authors:  B A Collin; H L Leather; J R Wingard; R Ramphal
Journal:  Clin Infect Dis       Date:  2001-09-05       Impact factor: 9.079

5.  Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study.

Authors:  Christian Junghanss; Kieren A Marr; Rachel A Carter; Brenda M Sandmaier; Michael B Maris; David G Maloney; Thomas Chauncey; Peter A McSweeney; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2002       Impact factor: 5.742

6.  Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia.

Authors:  Vanderson Rocha; Myriam Labopin; Guillermo Sanz; William Arcese; Rainer Schwerdtfeger; Alberto Bosi; Niels Jacobsen; Tapani Ruutu; Marcos de Lima; Jürgen Finke; Francesco Frassoni; Eliane Gluckman
Journal:  N Engl J Med       Date:  2004-11-25       Impact factor: 91.245

7.  Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia.

Authors:  Mary J Laughlin; Mary Eapen; Pablo Rubinstein; John E Wagner; Mei-Jei Zhang; Richard E Champlin; Cladd Stevens; Juliet N Barker; Robert P Gale; Hillard M Lazarus; David I Marks; Jon J van Rood; Andromachi Scaradavou; Mary M Horowitz
Journal:  N Engl J Med       Date:  2004-11-25       Impact factor: 91.245

8.  Cytomegalovirus infection following unrelated cord blood transplantation for adult patients: a single institute experience in Japan.

Authors:  Akira Tomonari; Tohru Iseki; Jun Ooi; Satoshi Takahashi; Motohiro Shindo; Koji Ishii; Fumitaka Nagamura; Kaoru Uchimaru; Kenzaburo Tani; Arinobu Tojo; Shigetaka Asano
Journal:  Br J Haematol       Date:  2003-04       Impact factor: 6.998

9.  Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies.

Authors:  Satoshi Takahashi; Tohru Iseki; Jun Ooi; Akira Tomonari; Kashiya Takasugi; Yoko Shimohakamada; Toshiki Yamada; Kaoru Uchimaru; Arinobu Tojo; Naoki Shirafuji; Hideki Kodo; Kenzaburo Tani; Tsuneo Takahashi; Takuhiro Yamaguchi; Shigetaka Asano
Journal:  Blood       Date:  2004-07-27       Impact factor: 22.113

10.  Kinetics of myeloid and lymphocyte recovery and infectious complications after unrelated umbilical cord blood versus HLA-matched unrelated donor allogeneic transplantation in adults.

Authors:  Nashaat S Hamza; Michelle Lisgaris; Gopala Yadavalli; Laura Nadeau; Robert Fox; Pingfu Fu; Hillard M Lazarus; Omer N Koc; Robert A Salata; Mary J Laughlin
Journal:  Br J Haematol       Date:  2004-02       Impact factor: 6.998

  10 in total
  1 in total

Review 1.  Infectious Complications after Umbilical Cord-Blood Transplantation from Unrelated Donors.

Authors:  Juan Montoro; José Luis Piñana; Federico Moscardó; Jaime Sanz
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-10-18       Impact factor: 2.576

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.